Evonik RESOMER LR 706 S is a bioresorbable poly(L-lactide-co-DL-lactide) 70:30 medical-grade resin supplied as white to off-white granules for implantable medical devices, parenteral drug delivery systems, and controlled-release applications. The product is amorphous, with differential scanning calorimetry indicating a glass transition temperature of 55–60 °C and no crystalline melting endotherm. The manufacturer’s certificate-of-analysis specification places inherent viscosity at 2.5–3.5 dL/g when measured as a 0.1% w/v solution in chloroform at 25 °C. Residual monomer, water, and solvent are controlled to limits of 0.5%, 0.5%, and 0.1%, respectively. The 70:30 L-lactide-to-DL-lactide ratio disrupts chain stereoregularity and suppresses crystallization, producing near-isotropic mechanical behavior in molded, extruded, or cast forms. Because the polymer contains no glycolide, hydrolytic degradation releases lactic acid rather than glycolic acid. The medical-grade designation concerns purity, residual contaminant control, and supporting documentation; it does not imply that the raw granulate is sterile or that a finished device is cleared for clinical use.

These values are raw-material acceptance limits and do not replace device-level specifications. In the manufacturer’s standard specification, capillary viscometry serves as the primary molecular-weight surrogate because intrinsic viscosity correlates with chain length under defined solvent and temperature conditions. Differential scanning calorimetry confirms the absence of crystallinity, while Karl Fischer titration, high-performance liquid chromatography, and headspace gas chromatography control water, residual lactide monomers, and volatile process solvents. Metal residues are limited by inductively coupled plasma optical emission spectrometry, with tin controlled separately because organotin compounds are commonly used as polymerization catalysts. Biological reactivity data according to USP 88 Class VI are often supplied within change-control documentation for medical-grade materials; however, the finished implant, drug-device combination product, or parenteral formulation still requires biological evaluation under ISO 10993-1:2018.

What Distinguishes the 70:30 L/DL-Lactide Copolymer from Semicrystalline PLLA?

Compared with poly(L-lactide) homopolymer, RESOMER LR 706 S eliminates crystalline domains entirely. A PLLA homopolymer of analogous chain length typically shows a melting endotherm near 180 °C and may exhibit slower water penetration through ordered lamellae. LR 706 S, in contrast, shows only the 55–60 °C glass transition and permits hydrolytic degradation to proceed more uniformly across the polymer matrix. The absence of crystallinity reduces anisotropic mechanical behavior in injection-molded or solvent-cast parts and allows solvent removal or shaping at lower temperatures than semicrystalline PLLA. Compared with poly(lactide-co-glycolide) copolymers containing glycolide, LR 706 S degrades more slowly because the lactide backbone is more hydrophobic, and hydrolysis releases lactic acid rather than glycolic acid. This difference can moderate the local pH drop observed with glycolide-rich PLGA devices, although the magnitude is formulation-dependent.

Within the L/DL-lactide LR series, the 706 S code occupies a mid-viscosity position. Lower-viscosity grades are used when dilute solution injection, fine droplet formation, or reduced melt pressure is required. Higher-viscosity grades are selected where greater mechanical strength and longer degradation are primary requirements. The 2.5–3.5 dL/g inherent viscosity range of LR 706 S therefore supports a compromise between solution processability, melt extrusion behavior, and controlled-release control in extended-release systems. The chemical composition remains constant across the LR series; the principal difference between adjacent LR grades is molecular weight, not lactide stereochemistry or monomer ratio.

For oil-in-water microsphere fabrication, the polymer is dissolved in a volatile organic solvent at concentrations typically in the 5–20% w/v range; dichloromethane and ethyl acetate are common process solvents. The organic phase is emulsified into an aqueous continuous phase containing a stabilizer such as polyvinyl alcohol, after which solvent extraction and evaporation harden the particles. The inherent viscosity range of 2.5–3.5 dL/g directly influences organic-phase viscosity and droplet breakup in rotor-stator, static mixer, or membrane emulsification systems. Higher viscosity shifts particle size upward at fixed impeller speed, while lower viscosity can produce finer droplets but may reduce encapsulation efficiency for lipophilic actives. Dynamic viscosity of LR 706 S solutions is not provided as a single-point universal value, so formulation-specific rheology measurements under design-of-experiment methodology are required during scale-up. Residual solvent content in finished microspheres is controlled by gas chromatography and must comply with ICH Q3C or USP 467 residual solvent limits for the finished dosage form.

When Melt Extrusion Replaces Solvent Processing in Implant Manufacture

Residual moisture becomes a critical process variable when hot-melt extrusion is selected for drug-eluting implant or pellet manufacture. The certificate-of-analysis upper limit for water is 0.5% w/w; exceeding this value before melt processing can initiate hydrolytic chain scission and reduce molecular weight during extrusion. The amorphous granules are therefore vacuum-dried below the 55–60 °C glass transition temperature, typically in a vacuum oven at pressures below 10 mbar, until the water limit is restored. Twin-screw extruders with L/D ratios from 25:1 to 40:1 are commonly used for dispersing heat-sensitive active pharmaceutical ingredients into the polymer matrix. The mid-range viscosity of LR 706 S raises melt pressure relative to lower-IV grades, and strand pelletizing may require water bath temperatures below 25 °C to prevent strand tackiness.

Batch-to-batch variation within the 2.5–3.5 dL/g specification can shift melt pressure, torque, and strand diameter. Production-scale operators commonly adjust barrel temperature set points by 5–10 °C or modify screw speed to maintain strand geometry and pellet quality. Prolonged exposure at elevated melt temperatures promotes thermal degradation of the aliphatic ester backbone, so screw configuration, barrel residence time, and specific mechanical energy input must be controlled. Capillary rheometry at controlled residence time is more informative for this material than ISO 1133-1:2022 melt flow rate testing, because standard melt flow test temperatures may introduce degradation during the measurement itself. The amorphous nature of the copolymer also means that no semicrystalline reinforcement masks early thermal or hydrolytic damage, so viscosity reduction during processing is detected more directly in torque and die pressure trends.

Gamma irradiation at doses commonly used for terminal sterilization, such as 25 kGy, can reduce molecular weight and alter mechanical behavior through chain scission. Dose-setting studies under ISO 11137 should therefore include post-irradiation viscosity, strength, or degradation profiling from the final device geometry rather than from raw granulate alone. Ethylene oxide processing may require elevated humidity and temperature; for LR 706 S, the amorphous glass transition of 55–60 °C limits practical chamber temperature if shape distortion is to be avoided during sterilization. Steam autoclaving is generally unsuitable for this polyester because moisture and high temperature accelerate ester hydrolysis. Published data on terminal sterilization of LR 706 S in specific implant geometries is limited; cycle development is device-specific and cannot be inferred from raw-material stability data alone.

Regulatory and Residual Contaminant Limits

Medical-grade status is supported by supply under a quality management system certified to ISO 13485:2016; it is not conferred by raw-material certification alone. Biological evaluation of the finished device follows ISO 10993-1:2018, and the polymer may be tested according to USP 88 Biological Reactivity Tests for Class VI plastics. Cytotoxicity, sensitization, implantation, and systemic toxicity endpoints are evaluated on the final product because processing residues, sterilization changes, and geometric factors can alter biological response. Residual tin catalyst is controlled at ≤200 ppm and heavy metals at ≤10 ppm to limit extractable metal burden. Residual monomer and solvent limits are specific to the medical grade and must be considered alongside finished-product monographs or ICH Q3C residual solvent guidance when solvent-based processing is used.

Storage conditions materially affect process repeatability. The granules are supplied in sealed packaging intended to exclude humid air. At relative humidity above 60%, moisture uptake can exceed the certified 0.5% water limit and require re-drying before melt processing. The polymer should not be held in aqueous media above pH 7 for prolonged periods before intended resorption, because alkaline conditions accelerate ester hydrolysis and can reduce molecular weight unpredictably. These constraints apply to raw material handling and to intermediate manufacturing steps such as aqueous emulsion hardening or buffer exposure during coating.

Production-scale handling on hot-melt extrusion lines has shown that the amorphous granules can become tacky when exposed simultaneously to warmth and humidity; sealed storage and controlled room-temperature handling are therefore part of the standard material procedure. In solvent-based microsphere processes, batch-to-batch variation within the 2.5–3.5 dL/g specification can shift particle size distribution if emulsification speed or organic-phase concentration is not adjusted for the actual certificate-of-analysis viscosity. The final application of RESOMER LR 706 S as a bioresorbable L/DL-lactide medical product depends on device configuration, sterilization modality, drug-polymer interaction, and regulatory submission; no single processing cycle defines the material across all applications.